Spyre Therapeutics, Inc. SEC filings SYRE

Spyre Therapeutics, Inc. has 823 filings in SEC EDGAR's recent list, going back to Mar 24, 2015. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.

Spyre Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 10, 2026 Dec 31, 2025
10-K Annual report Feb 19, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 14, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
10-K/A Amended annual report Nov 18, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 2, 2024 Dec 31, 2023
10-K/A Amended annual report Mar 1, 2024 Dec 31, 2023
10-K Annual report Feb 29, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 17, 2023 Dec 31, 2022
10-K Annual report Mar 2, 2023 Dec 31, 2022
10-K Annual report Mar 8, 2022 Dec 31, 2021
10-K Annual report Mar 18, 2021 Dec 31, 2020
10-K Annual report Feb 24, 2020 Dec 31, 2019
10-K Annual report Mar 7, 2019 Dec 31, 2018
10-K Annual report Mar 13, 2018 Dec 31, 2017
10-K Annual report Mar 23, 2017 Dec 31, 2016

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SYRE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Large accelerated filer
SEC CIK
1636282
Former names
Aeglea BioTherapeutics, Inc. (until Nov 24, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.